Introduction
Influenza is caused by RNA viruses belonging to the family of Orthomyxoviridae. Three types of influenza viruses can be distinguished. Among these, influenza A (IAV) viruses mainly infect birds and mammals, whereas influenza B viruses almost only infect humans. Influenza A virus displays constant evolutionary changes, defined as "antigenic drift" [1] and "antigenic shift" [2] , enabling new mutant strains to emerge and spread. Influenza viruses constitute a public health problem, as they can give rise to both epidemics and pandemics, causing high rates of morbidity and mortality [1] . Influenza viruses are considered the leading cause of respiratory illness in humans and are responsible for annual seasonal outbreaks that have a serious economic impact [3] . The average global burden of influenza may be in the order of 1 billion cases of flu, 3-5 million cases of severe illness that need hospitalization and 250,000-500,000 deaths yearly [4] . The most effective means of fighting influenza is primary prevention through vaccination [5] , which can prevent the disease after exposure or reduce the severity of symptoms. Antiviral drugs can also be used [6] . Indeed, in subjects who are not completely protected by vaccination strategies, an important role has been played by antiviral treatments [7] . Currently, two main classes of antiviral drugs are available; these are based on the ability to block viral M2 ion channels [8] and viral neuraminidase [9] . However, both classes of drugs have been associated with limited efficacy, adverse side effects [1] and the spread of drug resistance in circulating influenza viruses [10, 11] ; this last problem has been associated with an uncontrolled administration of the drugs to humans and, sometimes, to farm animals [12] . Other classes of drugs can be used against influenza virus, some of these include: inhibitors of hemagglutinin, endosomes, lysosomes, proteases, polymerases, nucleoprotein (NP), nonstructural-1 (NS1) glycoprotein, RNA synthesis and caspase; however their efficacy in blocking Influenza virus and avoiding the development of antiviral resistances should be further investigated [13] . It is therefore necessary to develop new anti-influenza treatments that are able to inhibit the replication or cellular processes of viruses [1, 7] . Some studies have indicated that certain plant extracts are able to mimic the anti-neuraminidase effect of antiviral drugs. One of these plants is sea buckthorn (SBT) (Hippophae rhamnoides): commonly known as sea buckthorn, it belongs to the family Elaeagnaceae [14] and it is a shrubby to bushy plant that grows also at a high altitude and is widely distributed in Eurasia. In India this plant grows predominantly in several high-altitude areas such as Sikkim, Himachal Pradesh, Kashmir, Jammu, and Uttar Pradesh but Hippophae is cultivated worldwide for its medicinal properties [15] .
All parts of SBT contain large amounts of several active compounds [16] and these include: vitamins (folic acid, vitamin C, vitamin A, vitamin E, vitamin K, riboflavin), carotenoids (lycopene α, β, δ-carotene), phytosterols (amyrins, ergosterol, stigmasterol, lansterol), organic acids (malic and oxalic acids), polyunsaturated fatty acids and essential amino acids [17] . Several medicinal and therapeutic applications utilize the extracts obtained from the leaves of this plant, which display immunomodulatory [18] and anti-inflammatory [19] properties, as demonstrated by Padwad and colleagues [16] . Furthermore, SBT leaves also exert antiviral, anti-bacterial and anti-tumor effects [20, 21] . Preliminary results have also shown that SBT seed extracts have anti-bacterial activity (for example against Listeria monocytogenes and Yersinia enterocolitica) [22, 23] and anti-viral activities, as reported by the group of Jain against Dengue virus [24] . SBT bud extracts are present in commercial dietary supplements, such as preparations of nutrient and vitamin products [25, 26] , and are formulated into Influpirinviral ® (PoolPharma). However, no data are currently available on the putative antiviral activity of bud extracts when taken in the form of dietary supplements. The aim of the present study was to evaluate the therapeutic anti-viral potential of SBT bud extracts on Influenza A/H1N1 virus infection in Madin Darby Canine Kidney cells (MDCK). In 2009, this viral strain was responsible for an Influenza pandemic that spread rapidly around the world [27] . Moreover, it currently circulates in the population, causing seasonal outbreaks, and its antigens are included in the available seasonal influenza vaccines [28] .
Methods

Cells and Cell Cultures
Madin Darby Canine Kidney (MDCK) cells were purchased from Sigma-Aldrich (ECACC, Public Health England, Porton Down, United Kingdom) and cultured in Minimum Essential Medium Eagle (EMEM medium) supplemented with 2mM Glutamine, 10% Fetal Bovine Serum (FBS) EU Approved (Euroclone, Pero, Italy) and 100Ul/ml of penicillin-streptomycin. Sub-confluent cultures (70%-80%) were grown at 37°C in a humidified atmosphere containing 5% CO 2, and subcultures were performed every 3-4 days [29] . Except where indicated otherwise, all the above reagents were from Lonza (Verviers, Belgium).
SBT bud dry extract
SBT bud dry extract from PoolPharma S.r.l. (San Giuliano Milanese, Italy) was weighed on a precision scale and dissolved in sterile Dulbecco's Phosphate-Buffered Saline (DPBS) at a final concentration of 1 mg/ml; the pH of the solution was measured (6.96). The dissolved extract was then sterile-filtered through a 0.22 µm filter.
Influenza A/California/7/2009 (H1N1) virus
Influenza A/California/7/2009 (H1N1) virus was obtained from the National Institute for Biological Standards and Control (NIBSC) (Potters Bar, Hertfordshire, United Kingdom) and used according to the instructions provided by the supplier. The virus was propagated in MDCK cells [30] , harvested and stored at -80°C. The propagated virus had a tissue culture infectious dose (TCID50) titer of 10 3.5 .
Viral growth
Influenza A/California/7/2009 (H1N1) virus was propagated in MDCK cells cultured in UltraMDCK serumfree-medium (SFM) supplemented with 0.5 μg/ml of trypsin from bovine pancreas (TPCK) (Sigma-Aldrich, Saint Louis, MO, USA) and 100 UI/ml of penicillinstreptomycin. MDCK cells were seeded in a T25 cm 2 tissue culture flask at a density of 1 x 10 6 cells/ml. After 24 hours (h), the cell medium was discarded and the cells were washed twice with sterile DPBS. After the DPBS had been discarded from the flask, the cells were treated with 500 µl of virus inoculum (5 ml of solution contained 50 µl of virus at 10 3.5 TCID50/ml (1:100 dilution) and 2.5 µl of TPCK, and incubated for 1 h at 37°C in 5% CO 2 . After 1 h, the inoculum was removed, the cells were washed with DPBS, and fresh UltraMDCK SFM, supplemented as previously described, was added. The cells were incubated at 37°C in 5% CO 2 and the cytopathic effect was monitored every day until postinfection day 4. The culture medium was collected and analyzed for TCID50 and hemagglutination titer on the 4 th day after infection.
Effect of SBT bud dry extract on MDCK cells MDCK cells were seeded at a density of 6.5 x 10 5 cells/ ml in 6-well plates in complete EMEM medium and were incubated for 24 h at 37°C in 5% CO 2 . SBT at different concentrations (1 μg/ml, 5 μg/ml, 10 μg/ml, 30 μg/ ml, 50 μg/ml, 75 μg/ml and 100 μg/ml) was then added to the medium in the wells. The cells were checked at 24 h, 48 h and 72 h by means of a light optical microscope to evaluate whether the extract had a cytotoxic effect on them. The experiment was repeated to confirm the preliminary results.
Effect of SBT on viral growth
The viral growth procedure was repeated in the conditions reported above. After infection, the inoculum was removed and the medium was replaced with fresh Ultra-MDCK SFM (supplemented with 100 UI/ml of penicillin-streptomycin and 0.5 g/ml of TPCK) containing different concentrations of SBT: 2.5 μg/ml, 5 μg/ml, 7.5 μg/ ml, 10 μg/ml, 30 μg/ml, 50 μg/ml, 75 μg/ml and 100 μg/ ml. The infection grade was observed daily for cytopathic effect, and the culture medium was harvested on day 4 to be analyzed for virus content in terms of TCID50 and hemagglutination titer. In parallel, two control flasks were run: the first flask represented the cell control and the culture medium was added with DPBS; the second flask represented the virus growth control and it was treated only with the live virus.
Virus titration by hemagglutination test
The ability of the influenza virus to agglutinate red blood cells from certain mammalian or avian species can be exploited to check for the presence and hemagglutinating activity of the virus in biological substrates (e.g. serum samples) [31, 32] . To evaluate the hemagglutinating capability of the virus in previously infected cell cultures, the hemagglutination test was used: 100 µl of culture medium from the flask of interest was transferred to the 1 st well of 12 of a 96-well V bottom plate then 50 μl of saline solution (0.9% NaCl) (Sigma-Aldrich, Saint Louis, MO, USA) was added from well 2 up to well 12; 2-fold serial dilutions of the culture medium (contained in the 1 st well) in the saline solution (wells 2-12) were performed from the 1 st well up to the 12 th well. Then, 50 µl of turkey red blood cell (RBC) suspension (0.5% in saline solution) (Emozoo Snc, Casole d'Elsa, Italy) was added to each well and the plate was incubated for 45 minutes at room temperature (RT). After incubation, the plate was tilted to allow non-hemagglutinated RBCs to drip from the bottom of the wells and the result was read; the reciprocal of the highest dilution of the culture medium that was still able to cause agglutination indicated the titer of the virus in the culture medium. The experiment was repeated, this time with a 1:10 starting dilution of the culture media, and the virus titer was calculated in terms of hemagglutinating units (HAU) in 1 ml by applying the following formula: HAU in 1 ml=20x10
[LOG(Dilution1)+LOG(Dilution2)]/2 .
Virus titration by TCID50
The "TCID50" titer is the viral dose that gives rise to a cytopathic effect in 50% of cells in the inoculated culture. The virus titer was determined by means of the TCID50 assay, using the Spearman/Karber method [33] on treated MDCK cells, as reported by Lugovtsev [34] . Twelve plastic tubes (1.5 ml) were prepared and loaded with 900 μl of cell medium (EMEM), except for the 11 th tube; 100 µl of supernatants from cultures was then transferred into the first tube and serial 10-fold dilutions were performed from tube 1 to up to tube 10. The contents of the tubes were transferred into a 96-well cell culture plate: the content of the 1 st tube was transferred into the 1 st column of the plate, the content of the 2 nd tube was transferred into the 2 nd column, and so on up to the 10 th tube. The 11 th column was left empty. At the end of the dilution steps, 100 μl of cell suspension (in complete EMEM medium, with 0.5% FBS and 0.5 μg/ml of TPCK, at a cell density of 5 x 10 5 cells/ml) was added to each well. The 12 th column, containing only cell medium and cell suspension, was used as a cell control. The plates were incubated for 5 days and the TCID50 titer was evaluated by checking the cytopathic effect in the cell mono-layer by means of a light microscope. The results were calculated by applying the Spearman/ Karber formula [33] : TCID50/100µl= X 0 -d/2+d(ΣXi/n), where X 0 is the positive logarithm of the highest dilution at which all wells are positive for cytopathic effect, d represents the dose distance in log, n is the number of repeats per dilution and ΣXi is the sum of all positive wells, starting from X 0 . In the case of 10-fold dilution, d=log 10 10=1 and the formula can be simplified to TCID50/100μl= X 0 -1/2+(ΣXi/n). To express the results as TCID50/ml, one log was added.
Results
Evaluation of the cytotoxic effect of SBT on MDCK Cells
The possible cytotoxic effect of SBT on MDCK cells previously infected with Influenza A H1N1 virus was evaluated by means of direct observation of cells under a light optical microscope. SBT treatment of MDCK cells showed no cytotoxic effect up to a concentration of 50 µg/ml. At 75 μg/ml and 100 μg/ml, SBT had a cytotoxic effect on the cells: at 75 μg/ml, the cell monolayer had a discontinuous appearance and floating cells were present in the culture medium; this effect was more evident at a concentration of 100 μg/ml (Tab. I).
SBT effect on viral growth results
Hemagglutination titer results
The ability of SBT bud extract to reduce Influenza H1N1 viral growth was evaluated on post-infection day 4. MDCK cell culture supernatants were harvested from the culture plates and assayed for hemagglutination titer. Concentrations of SBT ranging from 2.5 μg/ml to 50 μg/ml markedly reduced the hemagglutination titer from 28621.6 HAU/ml (the value obtained from the viral growth control sample) (Fig. 1) . The two highest concentrations of SBT used (75 μg/ml and 100 μg/ml) completely inhibited viral growth. However, they disTab. I. evaluation of the cytotoxic effect of SBT on mdCK Cells. This table shows the effect of different concentrations of SBT on mdCK cell cultures after 72 h of incubation. The concentrations of SBT tested were: 1 μg/ml, 5 μg/ml, 10 μg/ml, 30 μg/ml, 50 μg/ml, 75 μg/ml and 100μg/ml. No toxic effect was observed up to a concentration of 75 μg/ml. At 75 μg/ml and 100 μg/ml of SBT, the cells in the wells showed signs of toxicity: discontinuous cell layer and floating cells in the medium.
SBT concentration effect Cell control
No effect 1 µg/ml No effect 5 µg/ml No effect 10 µg/ml No effect 30 µg/ml No effect 50 µg/ml No effect 75 µg/ml discontinuous cell layer, floating cells 100 µg/ml discontinuous cell layer, floating cells played a toxic effect on the cells; the results obtained at these high concentrations may therefore be affected cell toxicity, as was observed after staining the cell cultures with Trypan blue.
TCID50 virus titration results
Cell culture supernatants were harvested on day 4 after infection and treatment and assayed for TCID50 virus titer to assess the number of infectious (live) viral particles released from the infected cells in the culture medium. The cytopathic effect was evaluated on day 5. The treatment of viral cultures with SBT at a concentration of 50 µg/ml markedly reduced the viral titer in terms of TCID50 (Fig. 2) . At 75 µg/ml and 100 µg/ml, SBT was able to inhibit viral growth completely; however, this value could be affected by the toxicity that SBT showed on cells at such high concentrations. Direct observation of the viral cultures confirmed the results obtained from TCID50 and hemagglutination titration. The concentration of SBT that proved to have the greatest impact on viral growth while exerting little negative effect on cells was 50 µg/ml. 
Discussion
In recent years, since the spread of resistant viral strain towards the available pharmacologic treatments and the occurrence of unpredictable pandemics, many investigations have been carried out on new computer-designed molecules or available compounds in a search for new The values of the TCId50 titer in 1 ml are shown on the y axis; on the x axis the concentrations of SBT used to treat viral cultures are reported: 0 μg/ml (virus control), 2.5 μg/ml, 5 μg/ml, 7.5 μg/ml, 10 μg/ml, 30 μg/ml, 50 μg/ml, 75 μg/ml and 100 μg/ml. The virus control displayed a titer of 102.5 TCId50; the TCId50 titer was reduced when SBT was used at a concentration of 50 μg/ml. At 75 μg/ml and 100 μg/ml, SBT inhibited viral growth totally. These results represent a mean of two experiments (n = 2). Fig. 1 . hemagglutination Titration results on day 4 after SBT treatment. Supernatants of viral cultures treated with SBT were analyzed by means of hemagglutination assay to determine whether the treatment was able to reduce the spread of Influenza virus. The values of the hemagglutination titer in 1 ml (volume assayed) are shown on the y axis; the x axis reports the concentrations of SBT (2.5 μg/ml, 5 μg/ml, 7.5 μg/ml, 10 μg/ml, 30 μg/ml, 50 μg/ml, 75 μg/ml and 100 μg/ml) used to treat viral cultures. No SBT was added to the virus control sample. The control sample displayed a titer of 28636; treatment with SBT dramatically decreased the hemagglutination titer. The most effective concentration of SBT was 50 μg/ml. At 75μg/ml and 100μg/ml, SBT totally inhibited viral growth, but in these cases the results could be affected by SBT toxicity. These results represent a mean of two experiments (n = 2).
anti-influenza drugs. In the present study, the antiviral activity of SBT bud extract (contained in Influpirinviral ® ) against influenza H1N1 A/California/7/2009 was evaluated in vitro on MDCK cells infected with this virus. A previous study conducted by Jain and colleagues [24] demonstrated that SBT leaf extract at a concentration of 50 μg/ml exerted an antiviral activity against Dengue virus. We found that SBT bud extract had an antiviral activity on influenza virus H1N1, especially at 50 μg/ml (the same concentration used by Jain's group). Specifically, after 4 days the viral titer was evaluated in terms of TCID50 titer and hemagglutination titer upon treatment with SBT bud extract; both methods revealed that, at 50 μg/ml, the viral titer was reduced in comparison with the virus control. Direct observation of the virus cultures confirmed the antiviral activity at 50 μg/ml, although an antiviral effect was also visible at lower concentrations, starting from 2.5 μg/ml. When SBT was used at high concentrations (75 μg/ml and 100 μg/ml), viral growth was completely inhibited. However, the treatment had an adverse effect on cell cultures, and this could have affected the results obtained at these concentrations.
Conclusions
The data obtained from this preliminary study confirmed that SBT bud extract has an antiviral activity on influenza H1N1 A/California/7/2009 in vitro, supporting its potential use as an anti-influenza agent. Nevertheless, further investigations are needed in order to generate more data, to evaluate the preventive role of SBT treatment against Influenza infection, and to understand the specific mechanism of action of this extract both in vitro and in vivo.
